Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow TRAX by emailGet an email when TRAX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about TRAX, unsubscribe in one click. Privacy
📣 What TRAX Says Is Next
Q3 2027 · “Phase 1b trial in EoE ongoing o 50-patient cohort assessing one dose level of subcutaneously administered ANB033 vs. placebo (randomized 1:1) through 12 weeks o Top-line Phase 1b data anticipated in Q3 2027”
Company press release, Aug 12, 2026 · SEC filing
Q1 2027 · “Enrollment ongoing with top-line Cohort 2 data anticipated in Q1 2027”
Company press release, Aug 12, 2026 · SEC filing
Q1 2027 · “We anticipate reporting these data in Q1 2027, followed by top-line data from our Phase 1b trial of ANB033 in eosinophilic esophagitis in Q3 2027.” ANB033 (CD122 antagonist)”
Company press release, Aug 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full TRAX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRAX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.